<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Imagenebio, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/imagenebio-inc</link>
    <description>Latest news and press releases for Imagenebio, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 13 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/imagenebio-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d75df151cc36e475338ddc.webp</url>
      <title>Imagenebio, Inc.</title>
      <link>https://6ix.com/company/imagenebio-inc</link>
    </image>
    <item>
      <title>ImageneBio Announces $30 Million Private Placement</title>
      <link>https://6ix.com/company/imagenebio-inc/news/imagenebio-announces-dollar30-million-private-placement</link>
      <guid isPermaLink="true">https://6ix.com/company/imagenebio-inc/news/imagenebio-announces-dollar30-million-private-placement</guid>
      <pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
      <description>Private placement led by Coastlands Capital with participation from additional new and existing investors Proceeds will support further development of IMG-007</description>
    </item>
    <item>
      <title>ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/imagenebio-inc/news/imagenebio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
      <guid isPermaLink="true">https://6ix.com/company/imagenebio-inc/news/imagenebio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
      <pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
      <description>SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on March 16, 2026 the Company’s</description>
    </item>
    <item>
      <title>ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update</title>
      <link>https://6ix.com/company/imagenebio-inc/news/imagenebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-company-update</link>
      <guid isPermaLink="true">https://6ix.com/company/imagenebio-inc/news/imagenebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-company-update</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 GMT</pubDate>
      <description>SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update. Company Highlights The IMG-007 Phase 2b ADAPTIVE trial in adults with moderate-to-severe atopic dermatitis (AD) is ongoing at North American sites; the study began enrolling in mid-2025 with topline data expected in 2027. A recent blinded safety review showed a favora</description>
    </item>
    <item>
      <title>ImageneBio to Participate in Leerink Global Healthcare Conference</title>
      <link>https://6ix.com/company/imagenebio-inc/news/imagenebio-to-participate-in-leerink-global-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/imagenebio-inc/news/imagenebio-to-participate-in-leerink-global-healthcare-conference</guid>
      <pubDate>Thu, 26 Feb 2026 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida. Fireside Date: Tuesday, March 10Time: 3:00pm ESTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company de</description>
    </item>
    <item>
      <title>ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer</title>
      <link>https://6ix.com/company/imagenebio-inc/news/imagenebio-appoints-immunology-drug-development-veteran-dr-ben-porter-brown-as-chief-medical-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/imagenebio-inc/news/imagenebio-appoints-immunology-drug-development-veteran-dr-ben-porter-brown-as-chief-medical-officer</guid>
      <pubDate>Tue, 10 Feb 2026 05:00:00 GMT</pubDate>
      <description>Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead</description>
    </item>
    <item>
      <title>ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team</title>
      <link>https://6ix.com/company/imagenebio-inc/news/imagenebio-reports-third-quarter-2025-financial-results-and-provides-img-007-program-update-following-closing-of-reverse-merger-concurrent-financing-and-strengthening-of-management-team</link>
      <guid isPermaLink="true">https://6ix.com/company/imagenebio-inc/news/imagenebio-reports-third-quarter-2025-financial-results-and-provides-img-007-program-update-following-closing-of-reverse-merger-concurrent-financing-and-strengthening-of-management-team</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007</description>
    </item>
    <item>
      <title>ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences</title>
      <link>https://6ix.com/company/imagenebio-inc/news/imagenebio-to-participate-in-fourth-quarter-2025-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/imagenebio-inc/news/imagenebio-to-participate-in-fourth-quarter-2025-investor-conferences</guid>
      <pubDate>Thu, 06 Nov 2025 13:30:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences. 2025 Stifel Healthcare ConferenceFireside Chat: Thursday, November 13, 9:20am ESTNew York, NY</description>
    </item>
    <item>
      <title>Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million</title>
      <link>https://6ix.com/company/imagenebio-inc/news/inmagene-biopharmaceuticals-announces-completion-of-merger-with-ikena-oncology-and-concurrent-private-placement-of-dollar75-million</link>
      <guid isPermaLink="true">https://6ix.com/company/imagenebio-inc/news/inmagene-biopharmaceuticals-announces-completion-of-merger-with-ikena-oncology-and-concurrent-private-placement-of-dollar75-million</guid>
      <pubDate>Fri, 25 Jul 2025 15:00:00 GMT</pubDate>
      <description>The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) --</description>
    </item>
  </channel>
</rss>